Effect on Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis in Patients With Type 2 Diabetes Mellitus on Treatment With Gastric Inhibitory Polypeptide / Glucagon Like Peptide-1 Analogue (Tirzpatide)
Latest Information Update: 16 Jan 2024
At a glance
- Drugs Tirzepatide (Primary) ; Semaglutide
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Jan 2024 Status changed from not yet recruiting to recruiting.
- 10 Jan 2024 Planned End Date changed from 1 Feb 2025 to 1 Oct 2024.
- 09 Mar 2023 New trial record